Advertisement

Topics

Latest "International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients" News Stories

13:36 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients" found in our extensive news archives from over 250 global news sources.

More Information about International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients for you to read. Along with our medical data and news we also list International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients Clinical Trials, which are updated daily. BioPortfolio also has a large database of International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients Companies for you to search.

Showing "International Travel Patterns Risk Behaviour Breast Cancer Lymphoma" News Articles 1–25 of 32,000+

Tuesday 19th March 2019

Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of ...


VALBIOTIS Strengthens Its Supervisory Board with the Appointment of Agnès TIXIER

• 25 years of experience leading finance departments for international companies • Expertise in strategic and financial management for listed companies, particularly with the establishment of European public financing related to innovation Regulatory News: VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a French Rese...

Progress Made in Locally Advanced Pancreatic Cancer

Dae Won Kim, MD, highlights recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.


Day 2 #TwitterTakeover―@FJCarmonas here! During the past year we've made an effort to increase the clinical significance of the #Cancer studies published at the journal. Great experience attending clinical meetings & handling #clinicaltrials papers―Ch

Day 2 #TwitterTakeover― @FJCarmonas here! During the past year we've made an effort to increase the clinical significance of the #Cancer studies published at the journal. Great experience attending clinical meetings & handling #clinicaltrials papers―Check

Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge

Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.

Flatiron Health’s OncoEMR is Top-Rated for Overall Satisfaction by KLAS’ 2019 Medical Oncology Performance Report

Top Ratings in Key Performance Areas Reinforce Flatiron’s Long-Term Commitment to Community Oncology Flatiron Health today announced its electronic health record (EHR) OncoEMR®, outperformed all other vendors in 11 out of 20 “key performance indicators” in KLAS’ 2019 Medical Oncology Performance Report, including “Overall Product Quality,”...

Nyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy

MONT-SAINT-GUIBERT, Belgium, March 19, 2019 /PRNewswire/ -- Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio® system in Europe. The Genio® system is the world's first and only battery-free, leadless and min...

JPJ Group plc (JPJ) - International continues to drive growth

Edison Investment Research - Travel & Leisure - JPJ Group plc: Driven by an impressive 42% organic growth in the Vera&John division, JPJ reported FY18 revenue growth of 10% to £319.6m with an EBITDA margin of 35.3%. International now comprises 43% of revenues and we expect this to increase as the company diversifies away from the UK. Cash generation remains strong and adjusted net debt/EBITDA...

Physicians’ Education Resource® to Host First Annual International Congress on the Future of Neurology™

The first-of-its-kind continuing medical education-certified conference will feature 25 world-renowned experts across multiple therapeutic areas Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will host the first annual International Congress on the Future of Neurology™ conferenc...

Authorities raid Korean stock exchange over Samsung BioLogics IPO

Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.

The process of applying to a graduate programme in the United States can be confusing — especially for international applicants who might not get adequate guidance. @cromanpa provides five tips on how to nail your applications. https://go.nature.com/2Y6

The process of applying to a graduate programme in the United States can be confusing — especially for international applicants who might not get adequate guidance. @cromanpa provides five tips on how to nail your applications. https://go.nature.com/2Y6sYl9 

Better Therapeutics Publishes New Study Demonstrating Rapid Reduction in Blood Pressure Among Hypertensive Adults

Mean systolic blood pressure reduction was -11.5mmHg in systolic and -5.9mmHg in diastolic, with 90% of participants lowering blood pressure from baseline. SAN FRANCISCO (PRWEB) March 19, 2019 Today, Better Therapeutics, a company developing prescription digital therapeutics for the treatment of severe cardiometabolic diseases, announced the publication of its latest peer-reviewed clinical study ...

FDA Approves Genentech’s Tecentriq Plus Chemo as First-Line Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). Th...

Breast density assessment varies greatly by screening method and race

Fewer women are assigned to a dense breast category when evaluated with advanced mammographic screening technologies compared to standard digital mammography, according to a new U.S. study published in the journal Radiology. A woman's breast density, or...

3D mammography significantly reduces breast biopsy rates

The use of digital breast tomosynthesis (DBT), also known as 3-D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study published in the...

Researchers Find Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients

PLYMOUTH MEETING, Pa., March 19, 2019 /PRNewswire/ — New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score (RS) testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer …

Roche to Present Results of the Largest Safety Study of its Kind with Tecentriq in Patients with Metastatic Bladder Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced first results from SAUL, a Phase IIIb study evaluating the safety of Tecentriq® in approximately 1000 patients with locally advanced or metastatic urothelial carcinoma (mUC) including several clinically relevant populations reflective of real-world clinical practice (patients with renal impairment, poor performance status (ECOG PS 2), treated asy...

Puma Biotechnology Presents Interim Results from the Phase 2 Trial Evaluating Neratinib for HER2 Mutant, Metastatic Cervical Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting in Honolulu, Hawaii. “Neratinib in ...

Multiple Myeloma-Causing Plasma Cells Show Intense Uptake of Intravenous Liposomal Curcumin as Reported by SignPath Pharma, Inc. in Paper Published in the Cancer Research Journal “Anticancer Research”

SignPath Pharma, Inc. reported in the March issue of Anticancer Research* that its proprietary intravenous liposomal curcumin (LipoCurc™) concentrates very intensely in the malignant plasma cells that cause

Science snaps: Revealing a potential new marker for aggressive prostate cancer

Science blog Scientists are constantly looking for new ways to improve cancer treatment, particularly for aggressive tumours. But spotting which cancers are aggressive when they’re first diagnosed can be tough, particularly in prostate cancer. “One of the biggest challenges so far in

IRW-News: ICC International Cannabis Corp: International Cannabis unterzeichnet Lizenzvereinbarung mit Authentic Brands Group für Europa zur Entwicklung einer Reihe von CBD-Produkten; damit verdoppeln ...

IRW-PRESS: ICC International Cannabis Corp: International Cannabis unterzeichnet Lizenzvereinbarung mit Authentic Brands Group für Europa zur Entwicklung einer Reihe von CBD-Produkten; damit verdo...

SFA Therapeutics Wins Second Key U.S. Patent For Treatment of Chronic Liver Diseases

Targets Liver Cancer SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program, which utilizes microbiome-derived metabolite small molecules as drugs to modulate the body’s anti-inflammatory and immune systems (USPTO #10,231,941). As a result of this new patent, targeting Ffar...

Dormant Viruses Activate During Spaceflight

NewsHerpes viruses reactivate in more than half of crew aboard Space Shuttle and International Space Station missions.Contributed Author: 

Potential Leukemia Drug Target Found in Epigenetic Protein

Acute myeloid leukemia (AML) is an aggressive cancer that led to over 10,000 deaths in the United States last year. While AML is the most type of leukemia in adults, thankfully, overall, this disease is relatively rare accounting for only about 1% of all cancers. Though there are therapeutics available to treat AML, a new […] The post Potential Leukemia Drug Target Found in Epigenetic Protei...

Synaptive Medical Appoints Sandra Clarke, CPA, CMA as Chief Financial Officer

Synaptive Medical, a global pioneer in automated surgical planning and robotics, today announced the appointment of Sandra Clarke, CPA, CMA as Chief Financial Officer. “Ms. Clarke is an incredible addition to our team,” said Peter Wehrly, CEO of Synaptive. “With her accomplished background and experience working for companies at critical inf...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks